A randomized controlled trial of the effect of spironolactone on left ventricular mass in hemodialysis patients

Autor: Sebastian Toncar, Thomas Schmiedeke, Thomas Vogl, Nils Pollak, Michael Leidig, Beatrix Büschges-Seraphin, Marianne Kleinert, Cord Schneuzer, Christina Klaeffling, Clemens Grupp, Christoph Blaser, Susanne Berweck, Rüdiger Götz, Stefan Fischer, Andreas Schmitt, Bettina Wirth, Frank Breunig, Markus Ketteler, Hendrick Witsch, Frank Strutz, Uwe Malzahn, Oliver Jung, Markus Schneider, Julian Gebhardt, Jan Goßmann, Mohamed Marwan, Holger Naujoks, Mara Dörken, L. Schramm, Ewelina Sobkowiak, Michael Heckel, Joanna Harazny, Arnfried Klingbeil, J Zimmermann, Maria Moritz, Heribert Fink, Raoul Zeltner, Patrick Biggar, Rolf Janka, Ahmet Cakmak, Stefan Büttner, Christoph Betz, Fabian Hammer, Heike Schneider, Sarah Rudolf, Beate Schamberger, Imke Reimer, Claudius Kleinert, Michael Brunner, Sabine Schütterle, Susanne Schwedler, Vera Krane, Thorsten Klink, Sophie Richter, Christian Ritter, Markus Schöffauer, Tilo Freiwald, Helmut Geiger, Ulrike Raff, Benjamin-Florian Koch, Renate Hammerstingl, Thomas Bochannek, Joachim Hoyer, Wolfgang Freisinger, Paul Würmell, Daniel Sollinger, Vladimir Vasiljuk, Michael Schmid, Clemens Reichert, Jens Lutz, Stefan Störk, Reinhard Schneider, Andrea Heyd-Schramm, Thomas Döltz, Brigitte Moye, Kai-Olaf Netzer, Kai-Uwe Eckardt, Jurij Ribel, Christoph Wanner, Julian Donhauser, Thorsten Walther, Julia Weinmann-Menke, Judith Kosowski

Publikováno v: Kidney International. 95:983-991

Mineralocorticoid receptor antagonists have beneficial effects on left ventricular remodeling, cardiac fibrosis, and arrhythmia in heart failure, but efficacy and safety in dialysis patients is less clear. We evaluated the effect of spironolactone on

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::adc8f0e24798b6d023a9deb6f47218d3
https://doi.org/10.1016/j.kint.2018.11.025